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From a neurobiological perspective there is no such thing as bipolar disorder. Rather, it is
almost certainly the case that many somewhat similar, but subtly different, pathological
conditions produce a disease state that we currently diagnose as bipolarity. This hetero-
geneity – reflected in the lack of synergy between our current diagnostic schema and our
rapidly advancing scientific understanding of the condition – limits attempts to articulate an
integrated perspective on bipolar disorder. However, despite these challenges, scientific
findings in recent years are beginning to offer a provisional “unified field theory” of the
disease. This theory sees bipolar disorder as a suite of related neurodevelopmental condi-
tions with interconnected functional abnormalities that often appear early in life and worsen
over time. In addition to accelerated loss of volume in brain areas known to be essential
for mood regulation and cognitive function, consistent findings have emerged at a cellular
level, providing evidence that bipolar disorder is reliably associated with dysregulation of
glial–neuronal interactions. Among these glial elements are microglia – the brain’s primary
immune elements, which appear to be overactive in the context of bipolarity. Multiple stud-
ies now indicate that inflammation is also increased in the periphery of the body in both the
depressive and manic phases of the illness, with at least some return to normality in the
euthymic state.These findings are consistent with changes in the hypothalamic–pituitary–
adrenal axis, which are known to drive inflammatory activation. In summary, the very fact
that no single gene, pathway, or brain abnormality is likely to ever account for the condition
is itself an extremely important first step in better articulating an integrated perspective on
both its ontological status and pathogenesis. Whether this perspective will translate into
the discovery of innumerable more homogeneous forms of bipolarity is one of the great
questions facing the field and one that is likely to have profound treatment implications,
given that fact that such a discovery would greatly increase our ability to individualize – and
by extension, enhance – treatment.
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INTRODUCTION
Despite significant advances in our understanding of the under-
lying neurobiology of bipolar disorder, its timely diagnosis and
efficient treatment remain daunting clinical challenges. Multiple
psychiatric comorbidities, including attention deficit hyperactiv-
ity disorder (ADHD) as well as anxiety, personality, and eating
and substance use disorders, interfere with diagnosis and treat-
ment and likely contribute to increased disease morbidity and
mortality in general and to increased suicide risk in particular (1,
2). In addition to an increased risk of suicide, bipolar disorder is
also associated with considerable medical comorbidities, including
cardio- and cerebrovascular disease, and metabolic and endocrine
disorders, which, when combined with neuropsychiatric morbid-
ity and suicidality, have been found to reduce life expectancy by an
average of 11 years in females and 10 years in males afflicted with
bipolarity (1, 3).
These poor outcomes reflect our growing recognition, based on
neurobiological and neuroimaging research, which bipolar disor-
der is frequently an aggressive and corrosive condition. Epidemio-
logic studies suggest that repeated mood episodes and even minor,
residual symptoms enhance the risk of future recurrences (4–7).
Successive episodes have, in turn, produce detectable volumetric
changes in the brain that have been frequently associated with
deterioration in multiple functional domains (8–11). Moreover,
contrary to previous views, we now know that neuropsychological
deficits often persist even when individuals with the disorder are
in a euthymic state (12–14).
Unfortunately, our current diagnostic schema for bipolar dis-
order, which is based on descriptive nomenclature rather than
clearly delineated causal mechanisms, has not given rise to treat-
ments that provide sustained, symptomatic, and functional recov-
ery for many patients (15). Moreover, available pharmacologic
interventions are plagued by pronounced adverse effects that
often aggravate metabolic status and further compromise cogni-
tion in people already struggling in this domain (16–18). Finally,
treatment-related adversities and polypharmacy tend to translate
into sub-optimal treatment adherence (19).
Is there a way out of this vicious cycle? Fortunately, the prepon-
derance of genetic, neuroimaging, histological, and biochemical
studies provide a different perspective on bipolar disorder as a
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biologically diverse disease category. Greater understanding of the
important pathophysiological differences between bipolar sub-
types will increasingly help maximize treatment efficacy while
minimizing unwanted side effects and adverse events. Taken as a
whole, the current state of the science strongly suggests that rather
than being a single condition, the diagnostic entity we call bipolar
disorder is composed of diverse biological entities, with pheno-
typical manifestations similar enough to each other to fit under
the same diagnostic umbrella. This reframing of bipolar disorder
immediately raises questions. Does this perspective point to more
advantageous ways of diagnosing and/or treating the disorder?
For example, might it be that assuming an approach similar to
the one used to define and treat complex medical conditions may
be more fruitful than our current approaches to bipolar disorder?
Do we have sufficient knowledge to characterize bipolar disorder
based on its genetics, etiopathogenesis, pathophysiology, and alter-
ations on the cellular and subcellular levels? Given the genetic and
neurobiological diversity of bipolar disorder, is there a reasonable
hope that we can achieve anything more than a probabilistic asso-
ciation between pathophysiological underpinnings and clinical
manifestations of the condition?
Although the answers to these questions are not known with any
finality, we hope to demonstrate in this paper that a deeper under-
standing of the relationship between macroscopic and microscopic
brain changes (including alterations in cellular and subcellular sig-
naling) and the phenotypical manifestations of bipolar disorder
may open the possibility of developing more effective and less dis-
ruptive treatment approaches. Furthermore, we believe that the
brain network changes and alterations in neurotransmission that
are characteristic of bipolar disorder disrupt brain–body signal-
ing in ways that may in the future allow for novel therapeutic
methodologies that reverse the autonomic, neuroendocrine, and
immune systems that are characteristic of the disorder and that
almost certainly contribute to the high degree of medical mor-
bidity observed in bipolarity. Finally, we will attempt to establish
a link between macroscopic and microscopic brain changes and
the interaction between multiple genetic factors and life adversi-
ties (Figure 1). As a first step in realizing these aspirations, in this
paper, we review genetic, neuroimaging, pathohistological, neu-
roendocrine, and molecular research in hope of finding answers
that may be useful for helping bipolar patients in our everyday
clinical practices.
GENETIC FINDINGS IN BIPOLAR DISORDER
A strong genetic basis for bipolar disorder has been apparent since
researchers conducted the first familial and identical twin studies
many years ago. Identical-twin concordance rates for bipolar disor-
der generally range from 40 to 70%, with the estimated heritability
reaching as high as 90% in the most recent reports (20). How-
ever, despite these observations, the unambiguous identification
of single nucleotide (SNP) risk factors for the disorder has proven
remarkably difficult. Nonetheless, the “gold standard” genome-
wide association study (GWAS) approach, although initially dis-
appointing, has begun to yield consistent SNP and genetic pathway
findings for bipolar I disorder. Interestingly, however, although
some difference in genetic risks have been observed between bipo-
lar disorder and other currently recognized psychiatric disease
states, the more striking finding is the high degree of genetic
overlap between conditions. For example, a pronounced genetic
overlap, primarily between schizophrenia and bipolar disorder,
but also with major depressive disorder (MDD), has been recently
reported (21). Perhaps surprisingly, and contradicting traditional
FIGURE 1 | An etiopathogenesis-based understanding of mood
disorders. Descriptive models of mood disorders offer only minimal
treatment guidance. A model connecting genotype, epigenetic modification,
and multiple-level endo-phenotypical alterations to clinical presentation may
provide a path to greater treatment success. Our model acknowledges
pathophysiological diversity of mood disorders and provides opportunity for
individualized treatment approaches based on the link between symptom
constellations, genetics, and specific endo-phenotype markers.
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diagnostic schemes, a recent GWAS suggests that bipolar disor-
der is genetically more closely related to schizophrenia than MDD
(22). In general, GWAS suggest that both bipolar I disorder and
schizophrenia are characterized by polygenic inheritance, such that
many common variants, each with a very small effect size, con-
tribute to the disorders (23, 24). These genetic risks appear not
to be randomly scattered through the genome, but rather to coa-
lesce into functional pathways. For example, a recent GWAS found
evidence for enrichment of risk SNPS in the following pathways:
corticotropin-releasing hormone signaling, cardiac β-adrenergic
signaling, phospholipase C signaling, glutamate receptor signaling,
endothelin 1 signaling, and cardiac hypertrophy signaling (25).
And despite the high degree of genetic overlap between bipolar I
disorder and schizophrenia, recent GWAS also indicate the exis-
tence of non-shared polygenic pathways for each condition (26,
27). Moreover, recent studies indicate that large effect size copy
number variants are more common in schizophrenia, and that
schizophrenia may be more closely tied to central nervous sys-
tem (CNS) autoimmune processes (i.e., multiple sclerosis) than is
bipolar disorder (28, 29).
Not surprisingly, genetic studies have confirmed that bipolar
disorder is a highly heterogeneous condition (20, 30). At least
in part, this likely reflects the fact that several mechanisms of
inheritance are involved in propagating the condition. Aside from
complex interactions among the multitudes of single nucleotide
polymorphisms incorporated into genetic networks, also known
as genetic epistasis, structural genomic variations such as copy
number variants and epigenetic variation all seem to play a role in
the transmission of bipolar illness (20, 30, 31). Large-scale GWAS
have scanned hundreds of candidate genes with variable results.
Overall, GWAS have either failed to identify genes responsible
for bipolar disorder, due to relatively small individual contribu-
tions, inadequate sample size, or disease heterogeneity (21, 30),
or they have identified genes involved in “housekeeping” func-
tions, such as translation, transcription, energy conversion, and
metabolism (32). Genes involved in more brain-specific functions,
including transmission, cell differentiation, cytoskeleton forma-
tion, and stress response have also been implicated (31). From
these many studies, CACNA1C, a gene that codes for the alpha
subunit of the L-type voltage-gated Ca++ channel, has been the
most often replicated finding [Large-scale genome-wide associ-
ation analysis of bipolar disorder identifies a new susceptibility
locus near ODZ4 (20, 33, 34)]. Malfunction of CACNA1C has
been associated with cognitive and attentional problems, both of
which play a prominent role in bipolar psychopathology (35, 36).
A handful of other genes, including ODZ4, coding for cell surface
proteins involved in signaling and neuronal path finding, NCAN,
a brain-expressed extracellular matrix glycoprotein (rodents with
altered NCAN gene function show manic-like behaviors) and
ANK3, a gene involved in localization of sodium channels, have
had replicated GWAS support (20, 33, 34, 37, 38). Using a differ-
ent approach, some studies have focused on gene networks and
protein–protein interactions (39). For example, one study iden-
tified a set of disease markers for bipolar disorder that includes
SEC24C (involved in vesicular transportation from endoplasmic
reticulum to Golgi apparatus) andMUSK (which encodes proteins
responsible for receptor assembly in the neuromuscular junction)
(31). Several large studies have also implicated polymorphisms
of clock genes in the etiology of bipolar disorder (40). Given the
prominence of circadian dysregulation in cyclical mood disorders,
the involvement of these genes in the condition seems plausible.
With the caveat that candidate gene approaches have been
fast to identify risk genes for psychiatric disorders, but strikingly
slow to replicate these findings when they occur, it is nonethe-
less of some relevance to review the most consistent findings
from this approach. Candidate gene studies have identified a
number of genes, such as catechol-O-methyltransferase (COMT ),
brain-derived neurotrophic factor (BDNF), neuregulin-1 (NRG-
1), and disrupted in schizophrenia (DISC-1) that appear to be
shared risk factors for schizophrenia, bipolar disorder, and MDD
(41). In addition to COMT, bipolar disorder has been associ-
ated with polymorphisms in a number of other genes coding
for monoamine receptors, transporters, and synthetic and cata-
bolic enzymes, including monoamine oxidase (MAOA), dopamine
transporter (DAT ), serotonin transporter (5HTT ), tryptophan
hydroxylase (TPH2), and the D2, D4, 5HT4, and 5HT2A recep-
tors (42–45). A polymorphism of the 5HTT promoter has been
linked with antidepressant-associated mania, lithium prophylactic
efficacy, age of onset, and suicidality in bipolar illness (46–49).
A number of studies have found that the 66 Val/Met poly-
morphism of the BDNF gene, which has been associated with
the regulation of neural resilience, plasticity, and proliferation,
may be a risk gene for bipolar illness. Some of these studies have
found a relationship between the BDNF polymorphism and brain
morphology but not the disease state itself, whereas others have
associated it with bipolar etiology only through an interaction
with stressful life events (50–52). Furthermore, the BDNF poly-
morphism has been linked with disease severity, early adolescent
onset, a propensity toward rapid cycling, and greater cognitive and
executive function deficits in bipolar disorder (53–56).
Genes regulating glycogen synthase kinase-3 (GSK-3), a “pro-
apoptotic”(programed cell death) peptide and a functional“oppo-
nent” of proteins involved in neuronal plasticity development,
differentiation, and cytoskeletal assembly, have also been impli-
cated in bipolar etiology. Researchers have reported an association
between aGSK-3 polymorphism and psychotic symptoms, the reg-
ulation of gene expression, lithium responsiveness, and alterations
in white-matter microstructure in the context of bipolar illness (57,
58). Additional studies have reported linkages between genes regu-
lating glutamate transmission (GRIN1, GRIN2A, GRIN2B, GRM3,
and GRM4), the stress response (ND4, NDUFV2, XBP1, and
MTHFR), inflammation (PDE4B, IL1B, IL6, and TNF), apoptosis
(BCL2A1 and EMP1), and oligodendrocyte-mediated myelination
of white-matter tracts (eIF2B) in bipolar disorder (42, 59–62).
Epigenetic changes reflecting an alteration of gene expression
influenced by life events may play a significant role in different
phases of bipolar illness (63). Indeed, studies have established a
difference in the pattern of gene expression between the depressed
state vs. euthymia or mania (64, 65). Furthermore, repeated manic
episodes can cause oxidative damage to DNA, interfering with
future DNA methylation, hence limiting the possibility of turn-
ing certain genes off (66). For example, hypomethylation of the
COMT gene has been associated with both bipolar disorder and
schizophrenia (67).
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In summary, genetic studies of bipolar disorder have encoun-
tered numerous obstacles, in large part resulting from the need to
bridge phenotypic and etiological heterogeneities. Evidence points
to a complex polygenetic pattern of inheritance, involving a large
number of genes with small to moderate individual effects, mod-
ified by epistasis, epigenetic modifications, and interactions with
the environment. Findings have been inconsistent, but when pos-
itive have most often identified the “housekeeping” genes involved
in cellular metabolic activities, ion exchange, synaptic develop-
ment and differentiation, as well as genes regulating myelination,
neurotransmission, neuronal plasticity, resilience, and apopto-
sis. It is conceivable that genetic influences may be reflected
in an endophenotype (“hidden phenotype”) of bipolar disor-
der characterized by abnormal circadian and hormonal rhythms,
responses to medications, and specific gray- and white-matter
changes (42, 68–70).
STUDIES OF AT-RISK COHORTS
Due to the progressive nature of bipolar disorder and the substan-
tial morbidity and mortality, which accompanies this condition,
it would be important to identify its presence as early in the dis-
ease course as possible. The last decade has seen a burgeoning
research effort aimed at identifying genetic factors, phenotypical
manifestations, biomarkers, and a pattern of imaging alterations,
which would herald the onset of bipolar illness. Very sophisticated
studies, including microsatellite and high-density SNP genotypes,
combined with the whole genome sequence data of a large Old
Order Amish pedigree sample, failed to identify a particular set
of gene loci, which would identify at-risk individuals (71). Using
a different approach, researchers reported an association between
a bipolar polygenic risk score, derived from a large genome-wide
meta-analysis of an MDD population, with several clinical features
including early disease onset, severity, suicide attempts, recurrent
and atypical depression, subclinical mania, and psychosis. How-
ever, it is important to note that the maximal variance in these
traits attributable to this polygenic score was approximately in
the 1% range (72). Although slight in its explanatory power, this
polygenic analysis did confirm the findings of phenomenologi-
cal literature focused on differentiating between bipolar disorder
and MDD.
Attempts to predict bipolar disorder based on phenomeno-
logical criteria have met with variable success. One of these
studies noted a predictive value for Childhood Bipolar Ques-
tionnaire items reflecting changes in Sleep/Arousal, Harm to
Self and Others, Territorial Aggression, Anxiety, Self-esteem, Psy-
chosis/Parasomnia/Sweet Cravings/Obsessions, and Fear of Harm
(FOH). Children with FOH, compared to the ones without this
risk trait had elevated indices of depression and mania, possibly
reflecting a more severe future illness course (73). Another group
validated ultra-high-risk criteria in a group of help-seeking ado-
lescents (74). Utilizing bipolar-at-risk (BAR) criteria at baseline,
which include items reflecting genetic risk (first degree relative
suffering from bipolar disorder), depressive, cyclothymic, and
sub-threshold mania features, investigators prospectively, over a
12-month period, predicted first episodes of mania/hypomania
(74). While these are encouraging reports, two recent large
meta-analyses concluded that it still not possible to accurately
predict the development of bipolar disorder, based on the early
phenomenology (75, 76).
On the other hand, emerging evidence suggests that brain imag-
ing my hold predictive promise. For example, a radiological inves-
tigation comparing adolescents with high genetic risk for bipolar
disorder and schizophrenia with matched controls, found evidence
of significant reduction in coupling in both frontal–striatal and
frontal–parietal networks, as well as lower recruitment of DLPFC
during a sustained attention task (77). Furthermore, a reduction
in the volume of orbitofrontal cortex, an area that plays a pivotal
role in emotion regulation, was noted in healthy siblings of bipolar
patients compared with healthy controls, suggesting its association
with the heritability of this condition. Conversely, the same study
discovered that a greater size of DLPFC may reflect resilience from
bipolar illness, as it differentiated healthy from affected siblings
(78). Finally, a promising line of research proposes a multifac-
torial approach, by developing a predictive algorithm based on
familial/genetic factors, environmental adversity, early behavioral
phenotype, biological markers [inflammatory cytokines, BDNF,
markers of oxidative stress, and hypothalamic–pituitary–adrenal
(HPA) disturbance], and imaging data (79–82).
NEUROIMAGING IN PATIENTS WITH BIPOLAR DISORDER
Neuroimaging studies of bipolar disorder are frequently charac-
terized by equivocal findings and, in some instances, a failure to
replicate previous results. Furthermore, multiple factors confound
any attempt to integrate neuroimaging findings into a single the-
oretical paradigm. Chief among these is the fact that many studies
fail to unequivocally define the mood state of patients at the time of
scanning or fail to provide information on subjects’ age or medica-
tion status, all of which can impact brain activity. Differentiating
the effect of medication on the underlying pathophysiological
processes in bipolar disorder imaging studies is a daunting task.
The majority of subjects in the imaging studies are medicated,
quite often with more than one class of medication. In an ideal sce-
nario, one would conduct a comparison between medicated and
unmedicated bipolar patients and healthy control subjects. Such a
design would require that medications be gradually reduced and
discontinued prior to randomization. Ethical and clinical con-
cerns would prohibit researchers from discontinuing medications
in stable bipolar patients with a history of severe symptomatology,
prominent suicidality, difficult-to-treat psychosis, highly recurrent
disease, or rapid and polyphasic cycling. If these patients were to
be excluded, it would introduce a selection bias, since the studies
would represent only patients with a milder form of disease who
could better tolerate medication discontinuation (83).
Importantly, two recent reviews addressing the impact of med-
ication on imaging outcomes jointly indicate that medications
have a fairly discrete impact in functional and diffusion tensor
imaging studies. The impact of medication in functional imag-
ing is difficult to discern, since majority of the study subjects are
medicated, often with a combination of medicines. When there
is a measurable medication effect on neural function in bipolar
disorder, it is predominantly ameliorative or “normalizing” (83,
84). Findings of structural studies suggest an increase in vol-
ume of the brain areas involved in mood regulation, associated
with lithium use, and mostly inconclusive effects of antipsychotics
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and anticonvulsants (84). Medication effects were more readily
discernable in the longitudinal studies aimed at evaluating the
medication effect on blood oxygen level-dependent (BOLD) sig-
nals (84). Most bipolar studies have been conducted in patients
in euthymic or depressive states, given the difficulty of imaging
floridly manic subjects, including the fact that imaging stud-
ies require minimal head motion. Furthermore, since research
indicates that bipolar disorder is a progressive illness, possibly
characterized by disparate pathophysiologic substrates in differ-
ent phases of illness, one can make a case for stratifying the sample
based base on the stage of the illness (85, 86).
However,despite these obstacles, there are some consistent find-
ings regarding the impact of bipolar disorder on brain function
and structure. Global structural brain changes and alterations in
ventricle size have been a frequent finding, although not without
exceptions (87). Magnetic resonance imaging (MRI) studies indi-
cate that patients suffering multiple bipolar episodes had larger
lateral ventricles relative to patients who only experienced a single
episode or healthy controls (11).
CHANGES IN VENTRICULAR SIZE AND CEREBRAL GRAY
MATTER VOLUME
Strakowski et al. utilized MRI to compare cerebral ventricle vol-
umes in healthy controls vs. patients suffering their first bipolar
episode or those who had experienced multiple episodes (11). Lat-
eral ventricles were significantly larger in patients with multiple
episodes than in the first episode or healthy subjects. In particular,
increased volume of the lateral ventricles directly correlated with
the number of manic episodes the patients had suffered. These
findings have been supported by a different group of researchers
who also noted an association between ventricular volume and
number of previous affective episodes. Taken together, these stud-
ies indicate that bipolar illness may be progressive and deleterious,
contributing to brain tissue deterioration in the course of recurrent
episodes (8).
PHYSIOLOGICAL FUNCTION OF THE BRAIN NETWORKS
INVOLVED IN THE PATHOPHYSIOLOGY OF BIPOLAR
DISORDER
The clinical symptoms of bipolar disorder do not appear to be
correlated to changes in the function or structure of specific
brain areas. Rather, bipolar symptoms manifesting as emotional,
cognitive, behavioral, autonomic, neuroendocrine, immune, and
circadian disturbances better correspond to the dysfunction of
interconnected brain networks (88–90). One perspective empha-
sizes a critical role of two interrelated prefrontal–limbic networks
in the pathophysiology of bipolar illness. The first of these net-
works, commonly referred to as the Automatic/Internal emotional
regulatory network, consists of an iterative loop, which includes
the ventromedial prefrontal cortex (PFC), subgenual anterior cin-
gulate cortex (ACC), nucleus accumbens, globus pallidus, and
thalamus (this network has a significant overlap with the Salience
network described by other authors). This network modulates
amygdala responses to endogenously generated feeling states, such
as melancholic feelings induced by memories of past losses.
The second of these networks, commonly referred to as the
Volitional/External regulatory network, involves the ventrolateral
FIGURE 2 | Functional brain changes in bipolar disorder. Based on
Langan and McDonald (91). Illustration courtesy of: Roland Tuley, Fire and
Rain. Imaging studies of euthymic bipolar patients provide evidence of
compromised cognitive control, combined with increased responsiveness
of limbic and para-limbic brain regions involved in emotional regulation.
Brain areas associated with cognitive control, which manifest reduced
responsiveness, are labeled blue (dorsal ACC, DMPFC, and DLPFC). By
contrast, limbic and para-limbic brain areas involved in emotional regulation,
associated with greater responsiveness, are labeled in red (amygdala,
VLPFC, and ventral ACC).
PFC, mid- and dorsal-cingulate cortex, ventromedial striatum,
globus pallidus, and thalamus (90). The dorsolateral PFC, with
its connections to the ventrolateral PFC, is commonly described
as the origination point of the volitional/cognitive regulatory arc
(largely corresponding with Executive control network in other
publications) (90). In turn, the ventrolateral PFC network mod-
ulates externally induced emotional states, assists with volun-
tary (cognitive) emotional regulation, and suppresses maladaptive
affect. These two networks have shared components and collab-
oratively regulate amygdala responses in complex emotional cir-
cumstances (90). Components of this complex prefrontal–ACC–
pallido-striatal–thalamic–amygdala network have altered function
and structure in individuals suffering from bipolar disorder when
compared with healthy populations (Figure 2). Specific changes
in these structures will be reviewed in the following sections.
Another study compared within – and between – network con-
nectivity in bipolar and schizophrenic patients vs. a healthy control
sample (92). In addition to the Salience Network and Executive
control network, the default mode network (DMN) has received
a lot of attention in mood disorders, ADHD, and schizophre-
nia research. The DMN is composed of interconnected midline
structures, including the sgACC, ventromedial PFC (vmPFC),
dorsomedial PFC, precuneus/PCC complex, and mesotemporal
structures. Some of the better studied functions of DMN include,
self-reflection, processing social information, creative work, future
planning, reminiscing, and conjuring of autobiographical mem-
ories. Calhoun et al. have noted impaired interconnectedness
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of the anterior DMN areas such as ventral ACC and vmPFC,
with other DMN components in bipolar subjects, compared with
schizophrenic patients and healthy controls. Imaging was con-
ducted during an auditory selection task. Additionally, these inves-
tigators described altered functional connectivity related to bipolar
disorder in cognitive/executive prefrontal and parietal areas (92).
Albeit using different methodology, another group discovered
aberrant resting state functional connectivity within the cingulo-
opercular network and between, cingulo-opercular and cerebellar
networks, and cerebellar and salience networks in bipolar patients
compared to controls. Moreover, the latter two abnormal network
connectivities correlated with disorganization symptoms in bipo-
lar patients (93). The cingulo-opercular network is believed to play
a role in the initiation and maintenance of task performance, as
well as signaling the need for a change in cognitive strategy (93).
The most recent review of eight resting state functional net-
work fMRI studies in bipolar patients reconfirms the findings
of the above mentioned studies. The largest difference between
bipolar patients and control groups were seen in the connectivity
between ACC and mPFC, and the limbic structures. Further-
more, findings of aberrant intra-network homogeneity involving
the DMN of bipolar patients, was also reproduced (94). While
research into functional network connectivity has a potential to
offer a better understanding of the neural origins of the complex
cognitive, emotional, and physical symptoms of bipolar disorder,
it requires consensus about the composition of functional net-
works, better control of confounding factors and more consistent,
methodologically sound replications.
PREFRONTAL CORTICAL ABNORMALITIES IN BIPOLAR
DISORDER
Prefrontal cortical abnormalities are a common finding in bipolar
disorder. Imaging studies have reported functional and structural
changes in the vmPFC of adolescents and young adult bipo-
lar patients relative to healthy controls (95, 96). Dysfunction of
vmPFC activity may be common to mood disorders and indepen-
dent of mood state because it has been described in both unipolar
(97, 98) and bipolar depression as well as in the context of elevated
mood (95, 99). The vmPFC has rich reciprocal connections with
limbic formations and the hypothalamus. Together with the ACC
and amygdala, the vmPFC may belong to an integrative network
involved in processing emotionally relevant information, which
coordinates autonomic and endocrine responses and influences
behavior (100). Aberrant vmPFC activity in the context of bipo-
lar illness may therefore be reflected in compromised ability to
adapt to changes in emotional and social circumstances. Manic
patients tend to be excessively preoccupied by hedonic interests,
whereas depressed individuals demonstrate impaired emotional
and endocrine homeostasis. Furthermore, endocrine disturbances
are also a common feature of elevated mood states (101). The
vmPFC is also a source of feedback regulation to monoaminergic
brainstem nuclei, so its malfunction may be reflected in altered
neurotransmission (102).
The ventrolateral PFC is also often referred to as the lat-
eral orbital PFC. This frontal area appears to have a role in the
“top-down” and volitional regulation of affect, whereby it acts to
suppress maladaptive emotional responses (102). Its activity has
been reported to be both reduced and elevated in the depres-
sive state (103, 104) but appears to be predominantly decreased in
bipolar mania (90, 105, 106). Disinhibited and socially inappropri-
ate behaviors, commonly present in mania, may be attributable to
impaired ventrolateral PFC function (105). Most structural stud-
ies in bipolar adolescents have found a progressive reduction in
the volume of this formation, whereas adult studies have provided
equivocal findings (9, 87, 107). Some of the research indicates a
combined effect of age and duration of illness on deterioration of
volume in this brain region (9, 87, 107).
Decreased activity in the dorsolateral PFC in bipolar disorder
may be associated with compromised working memory, impaired
ability to sustain attention, and compromised executive function
(103, 108). The dorsolateral PFC, together with the dorsal ACC
and parts of the parietal cortex, is considered a component of the
executive–cognitive network, which is known to exercise a regula-
tory role over limbic formations (109). A decline in the thickness
of the dorsolateral PFC has been associated with bipolar illness
duration (110).
The ACC is located at the intersection of dorsal (predomi-
nantly cognitive) and ventral (mostly emotion-regulating) cere-
bral regions (90). Additionally, the ACC serves as a sort of“anatom-
ical bridge” that connects prefrontal cortical areas with subcortical
limbic regions (9). The subgenual (sgACC) (Brodmann area 25),
and subcallosal [alternatively labeled as pregenual (pgACC) ante-
rior cingulate cortices (scACC) (BA 24a and b)] are sometimes
jointly referred to as the ventral ACC. Rostral (rACC) and dor-
sal (dACC) (BA 24c and 32) are often identified as either dorsal
ACC or more recently as mid-cingulate cortex (MCC) (111–114).
As one would expect, dorsal and mid-cingulate areas are more
involved in cognitive processes, whereas ventral portions of the
ACC participate in emotional regulation. The dorsal, cognitive
division of the ACC may be involved in tracking crosstalk or
conflict between brain areas. If conflict is detected dACC may
engage lateral prefrontal cortical areas in order to establish con-
trol operations (111). Pregenual ACC (pgACC) and anterior MCC
are recipients of integrated intero- and exteroceptive information
from anterior insula, in addition to amygdala input (115, 116).
These integrative structures promote homeostatic efforts by main-
taining a dynamic subjective image of the state of the body and
the surrounding environment (116). Autonomic projections from
sgACC to the amygdala, PAG, and nucleus tractus solitarius (NTS)
in the medulla enable this “limbic” portion of ACC to instantiate
an adaptive response to negative emotional events (113). There is
some indication that ACC activation may be increased in mania
and decreased in bipolar depression. Moreover, ventral portions
of the ACC may be overactive even in the euthymic state, while
dorsal segments remain hypoactive (90).
As one might predict from its location, the ACC plays a key
role in cognitive–emotional integration and ongoing monitoring
of behavior. The subgenual ACC orchestrates behavioral adap-
tation following an assessment of the salience of emotional and
motivational information. The subgenual ACC also modulates
bodily sympathetic and neuroendocrine activity in accordance
with external conditions (117). The ACC and insula are the
two primary hubs of the Salience network, tasked with detect-
ing relevant changes in the internal and external environment

























































Maletic and Raison Integrated neurobiology of bipolar disorder
and generating an appropriate emotional response (118). Inap-
propriately modulated emotional responses to changes in the
environment and motivational difficulties in bipolar disorder may
be associated with altered ACC function and structure (119).
Structural studies have noted significantly decreased volume in
the subgenual ACC in bipolar patients (119). Some authors have
speculated that early morphological abnormalities of the ACC may
be markers of vulnerability for ensuing psychosis and emotional
dysregulation (9).
The imaging literature is beset with inconsistent findings
regarding hippocampal volume in bipolar disorder. Some stud-
ies have found enlargement, others have noted loss of volume,
and others have reported no difference in hippocampal size in
bipolar patients compared with controls (107, 120). There is some
indication of an age-related increase in hippocampal volume in
bipolar youths (121), and mood-stabilizing agents (e.g., lithium)
have been reported to increase hippocampal volume (122, 123).
Decreases of hippocampal volume in the adulthood of bipolar
individuals may be driven by a polymorphism of genes regulat-
ing BDNF function and may be localized to certain hippocampal
substructures (9, 107, 121).
As in other brain areas, structural changes of the amygdala may
reflect the progression of bipolar illness. Most of the volumetric
studies have reported that bipolar children and adolescents have
a smaller amygdala volume, whereas adults have a larger volume,
compared with matched controls (107, 124). Changes in amygdala
volume in adulthood may reflect the progressive course of bipolar
illness or may be a consequence of an ameliorative effect of med-
ication (9, 107). Functional studies have, for the most part, found
increased activity in limbic structures of bipolar patients in both
the manic (a more consistent finding) and depressed state (detailed
discussion will follow in this section). The amygdala is involved
in the assessment and interpretation of emotion, particularly the
emotional value of surprising or ambiguous stimuli. Clinical stud-
ies have provided evidence that patients with bipolar disorder often
have disproportionate emotional responses to changes in circum-
stances and difficulty interpreting the emotional meaning of facial
expressions (124). Because limbic structures have significant bidi-
rectional connections with the hypothalamus and autonomic bed
nucleus of the stria terminalis, one might speculate that limbic
dysregulation may contribute to the often-noted autonomic and
neuroendocrine dysregulation in bipolar patients (125).
Several subcortical structures appear to be affected by bipolar
illness. Functional imaging studies have reported decreased activa-
tion of caudate, putamen, thalamus, and globus pallidus in bipolar
patients performing a response inhibition task, and attenuated
ventral striatum responses to happy faces across the mood states
(90). A recent meta-analysis has provided conflicting data regard-
ing basal ganglia and thalamic activation in bipolar illness (126).
Volumetric imaging studies have provided evidence of decreased
nucleus accumbens in bipolar individuals compared with matched
healthy controls (87). Studies on morphological changes of the
basal ganglia and thalamus in bipolar disorder are both sparse
and contradictory (9, 87, 107). Although one of the studies dis-
covered enlargement of the anterior putamen and head of the
caudate in bipolar disorder, other researchers found no difference
in volume (9, 87, 107).
Rare functional studies have described either attenuated cere-
bellar activity in bipolar disorder or no difference from healthy
controls (126). Limited structural imaging studies have indicated
midline cerebellar atrophy in bipolar subjects. Vermal size appears
to be associated with the number of previous mood episodes (9,
87, 107, 120). Changes in cerebellar function and structure may
be of particular clinical relevance in bipolar disorder because the
cerebellar vermis has been linked to the production of automatic
emotional responses, including empathy with facial expressions
(125). Furthermore, cerebellar–thalamic–basal ganglia–cortical
circuits have been implicated in reward-based learning (127), so
their altered function may provide an explanation for the sig-
nificant association between bipolar illness and substance use
disorders.
Diffusion tensor imaging studies evaluating white-matter
tract microstructure in bipolar disorder have found wide-
spread abnormalities (128). Several studies have detected
alterations in white-matter tracts connecting the subgenual
ACC with the amygdala–hippocampal complex, frontal lobe–
insula–hippocampus–amygdala–occipital lobe and frontal lobe–
thalamus–cingulate gyrus in bipolar patients relative to healthy
controls (128–131). Furthermore, altered white-matter connectiv-
ity between the dorsal/medial ACC and posterior cingulate cortex,
as well as between the dorsolateral PFC and orbital PFC, has been
detected in bipolar disorder patients compared with healthy sub-
jects (132). Finally, disruption of white-matter fibers connecting
both medial (automatic) and lateral (volitional) PFC networks
with amygdala, striatum, and thalamus in bipolar patients rela-
tive to healthy subjects may reflect global deficits in prefrontal
regulation of limbic areas (129). The anatomical locations of
these white-matter abnormalities are consistent with clinically
observed impulsivity, affective reactivity, and aberrant process-
ing of emotional stimuli (128–131). White-matter changes appear
to be asymmetrical and present in the earliest stages of bipo-
lar illness, most likely indicating abnormal expression of myelin-
and oligodendrocyte-related genes (128–131, 133, 134). Consis-
tent with these observations, studies have established white-matter
abnormalities in at-risk children and impaired frontal white-
matter integrity in first-episode manic patients (90). In aggre-
gate, white-matter studies suggest a developmental disturbance
that precedes and possibly predisposes to mood dysregulation
and eventual onset of bipolar episodes (90). Furthermore, white-
matter changes may be state dependent, as one study reported ven-
tromedial prefrontal–striatal, inferior fronto-occipital, and infe-
rior and superior longitudinal fasciculi white-matter alterations in
the bipolar depressed state, differentiating it from both remitted
patients and healthy controls (135).
STATE OR TRAIT? – CHANGES IN BRAIN FUNCTION AND
STRUCTURE IN BIPOLAR MOOD STATES
Neuroimaging studies have provided a more detailed, although
still incomplete, understanding of the pathophysiological
processes that underpin different mood states in bipolar disor-
der. An increase in amygdala activity is a frequently described
feature of elevated mood in bipolar disorder (90). Although many
studies using activation paradigms noted an increased amygdala
response in mania, resting-state imaging did not detect increased
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amygdala activity compared with healthy controls (105, 106, 136).
Furthermore, several (but not all) imaging studies reported ele-
vated dorsal ACC activity in the context of bipolar elevated mood
compared with depressed patients or healthy individuals (90, 136,
137). Several other limbic and paralimbic areas, including insula,
hippocampus, putamen, and subgenual ACC, have been noted to
have greater activity in manic subjects than in healthy controls
(136, 137). Decreased ventrolateral PFC activity is another com-
mon feature of bipolar mania that differentiates it from depressed,
euthymic state, and healthy controls (99, 105, 106, 137). Further
extending these observations, a group of investigators has reported
that a decrease in ventrolateral PFC activation correlated with the
duration of the manic episode (105). Diminished activity of rostral
PFC either in the resting state or in response to negative emotional
stimuli was detected in mania compared with healthy controls (99,
136, 138). Moreover, resting-state hypoactivity of dorsolateral PFC
has been associated with mania in comparison with healthy con-
trols (106, 136). In summary, impaired prefrontal cortical function
in elevated mood states may result in compromised regulation of
limbic and paralimbic areas, manifesting as excessive emotional
reactivity, irritability, impulsivity, difficulty conforming emotional
responses to the social milieu, excessive indulgence of appetitive
drives, and cognitive/attentional impairment.
Bipolar depression shares some activity patterns with ele-
vated moods but also has some distinguishing features. Bipolar
depressed patients have demonstrated a greater amygdala response
to negative facial expressions than manic or healthy individuals
(137). Several studies have noted elevated activity in other limbic
and subcortical areas, including insula, ventral striatum, puta-
men, hypothalamus, and thalamus, in bipolar depression relative
to healthy controls (106, 137, 139). In support of this observa-
tion, a magnetic resonance spectroscopic (MRS) study revealed
elevation of glutamate/glutamine signal in the thalamus of bipolar
depressed patients (140). Others have reported conflicting findings
of diminished metabolism/blood flow in the insula, ventral stria-
tum, and subgenual ACC of depressed bipolar patients (141). Most
studies note diminished prefrontal cortical activity in dorsolateral
PFC, ventrolateral PFC, and dorsomedial PFC in depressed bipo-
lar patients compared with either euthymic patients or healthy
controls (90, 106, 141, 142). Decreased dorsolateral PFC activ-
ity during a working memory task correlated with the severity
of depression in bipolar patients, measured by a standardized
scale (143). Both elevation and decrease of vmPFC activation
have been detected in bipolar depression (138, 142). Interestingly,
a recent MRI study comparing bipolar depressed with euthymic
patients discovered decreased gray-matter volume of dorsomedial
PFC and dorsolateral PFC (144). These morphological alterations
completely mirror decreased function in dorsomedial PFC and
dorsolateral PFC and provide strong support for the hypothet-
ical impairment of neuroplasticity in bipolar disorder (144). In
conclusion, imaging data suggest that compromised activity in
prefrontal cortical areas may result in inadequate modulation
of limbic/subcortical areas, especially in response to negative life
events, contributing to maladaptive depressed mood and inade-
quate cognitive coping. Imaging data have so far provided evidence
that clearly distinguishes depression from the other mood states
in bipolar disorder.
Most of the studies examining neural function in the euthymic
state have noted decreased function in ventrolateral PFC, dorso-
lateral PFC, and hyperactivation of striatal regions (caudate and
putamen) (106). A couple of resting-state imaging studies have
made some intriguing discoveries. One group noted significant
hyperconnectivity between ventrolateral PFC and amygdala that
is, to a lesser degree, also modulated by connectivity through the
ACC (145). Aberrant connectivity of these components of the voli-
tional/external cortico-limbic network may be a trait feature of
bipolar disorder, possibly predisposing toward future mood insta-
bility in the face of stressful events. Moreover, a different group,
also utilizing functional imaging in resting-state euthymic, older
bipolar adults, discovered increased amygdala, parahippocampal,
and anterior temporal cortical activity, combined with decreased
dorsolateral PFC activity. Most of these findings are absent in the
younger euthymic bipolar population, pointing to the progres-
sive nature of bipolar disorder, whereby cortico-limbic dysfunc-
tion becomes consolidated over time into a trait-like pattern of
activity (146).
IMAGING DIFFERENCES BETWEEN BIPOLAR AND UNIPOLAR
DEPRESSION
Discriminating between bipolar and unipolar depressive episodes
remains a clinical challenge. Recent imaging studies may indicate
some important differences in the pathophysiology of these condi-
tions. An fMRI study used images of happy, sad, and neutral facial
expressions as a stimulus. Patients with unipolar depression man-
ifested increased amygdala activation in response to negative facial
expressions, whereas patients with bipolar depression demon-
strated a greater amygdala response to positive facial expressions
(147). Another study used fMRI to analyze whole-brain patterns of
activation and also noted that viewing intensely happy faces gen-
erated an activity pattern that differentiated bipolar depression
from MDD (148). Consistent with these observations, a different
group of authors noted greater amygdala activation in response to
angry expressions in MDD patients relative to a bipolar depressed
group (149). Furthermore, activation of medial and orbitofrontal
prefrontal regions in response to emotional stimuli contributed
to the diagnosis of unipolar depression (147). This finding is very
intriguing because both of these ventral PFC areas are compo-
nents of a neural network involved in the “automatic”/internal
regulation of emotion (90). Greater activation in dorsolateral and
ventrolateral prefrontal areas in response to positive and negative
emotional features contributed to a classification of the subject as
having bipolar depression. Both of these lateral PFC structures play
a critical role in volitional/external emotional regulation and have
been shown to have an exaggerated responsiveness to emotional
stimuli in the context of bipolar disorder (90). A computerized
automatic algorithm utilizing the above-mentioned information
was able to correctly categorize unipolar vs. bipolar depression
with up to 90% accuracy (147).
Connectivity between other components of the ventro-
lateral and ventromedial prefrontal networks (prefrontal–
cingulate–striatal–pallidal–thalamic–amygdala) may also differ-
entiate unipolar and bipolar depression (90, 150). The ACC is
at the crossroads between ventral (mostly emotional) and dor-
sal (predominantly cognitive) networks connecting prefrontal
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regulatory with subcortical integrative brain regions (90, 150).
Bipolar and unipolar depressed patients had significantly
decreased pgACC connectivity with dorsomedial thalamus, amyg-
dala, and pallido-striatum compared with healthy controls. Com-
pared with unipolar depression, bipolar depressed subjects had
significantly decreased connectivity between pgACC and amyg-
dala and dorsomedial thalamus (150) Moreover, a separate group
of investigators reported a more intense activation of ventral stri-
atal, thalamic, hippocampal, amygdala, caudate nucleus/putamen,
vmPFC, ventrolateral PFC, and ACC in bipolar depressed indi-
viduals compared with MDD and a healthy control group, espe-
cially in response to mildly and intensely fearful and sad, and
mildly happy expressions (104). In aggregate, these findings may
reflect a greater degree of impairment in the prefrontal–cingulate–
striatal–pallidal–thalamic–amygdala circuits in bipolar vs. unipo-
lar depression. Although evidence substantiates impairment of
both volitional and automatic prefrontal–limbic circuitry, the voli-
tional ventrolateral PFC-mediated network seems to be more com-
promised in bipolar than unipolar depression, possibly reflecting
compromised prefrontal regulation of the subcortical limbic areas,
manifested as more prominent emotional lability and reactivity in
this disease state.
In addition to functional differences, there are also structural
differences between unipolar and bipolar depression. Compared
with bipolar depressed subjects, those with MDD had fewer deep
white-matter hyperintensities, reflecting a lesser degree of white-
matter impairment. Additionally, bipolar depressed subjects had
increased corpus callosum cross-sectional area and decreased hip-
pocampus and basal ganglia relative to unipolar patients. Both dis-
orders manifested a larger lateral ventricular volume and increased
rates of subcortical gray-matter hyperintensities compared with
healthy controls (151).
SUMMARY OF IMAGING FINDINGS IN BIPOLAR DISORDER
Cumulative imaging evidence of functional, structural, and white-
matter abnormalities implicates a compromised integrity of
frontal–subcortical and prefrontal–limbic circuits in the patho-
physiology of bipolar disorder. Additional involvement of frontal–
basal ganglia–thalamic–cerebellar networks is likely. In summary,
structural and functional changes support an organic basis for
the emotional, cognitive, and neuroendocrine symptomatology
of bipolar illness (89, 90, 119). Both regional gray-matter and
white-matter changes appear to be present relatively early in dis-
ease development. Altered emotional homeostasis and cognitive
difficulties stemming from these prodromal functional changes
may compromise stress coping and social adaptation, hastening
the onset of bipolar illness. In some instances, there is evidence of
a cumulative effect of disease duration and the number of prior
episodes of brain function and structure.
PATHOHISTOLOGIC FINDINGS ASSOCIATED WITH BIPOLAR
DISORDER
Pathohistologic research has uncovered significant cell pathology
associated with bipolar disorder. It appears that all three of the
glial cell families may be affected, linking the pathogenesis of
the condition to abnormalities in astroglia, oligodendroglia, and
microglia (152–155). Postmortem studies of bipolar patients have
noted a reduction in both glial cell numbers and density (156).
Glial alterations have been reported in the subgenual ACC, dorso-
lateral PFC,orbitofrontal cortex,and the amygdala of unmedicated
bipolar patients (157, 158). Interestingly, one study found evidence
that treatment with lithium or valproate may mitigate some of
the glial loss (157). Furthermore, a significant 29% reduction in
oligodendroglia numerical density in the dorsolateral PFC white
matter was detected in bipolar patients compared with controls
(155). Evidence of diminished myelin staining in the dorsolat-
eral PFC and reductions of S100B immune-positive oligoden-
drocytes in the hippocampus of bipolar subjects further extend
these findings (159, 160). Indeed, convergent imaging, histologic
and imaging evidence indicates that oligodendroglial deficits may
be the key CNS cellular abnormality in bipolar disorder (60, 61,
161–163).
A postmortem study of suicidal bipolar, MDD, and schizo-
phrenic patients provided intriguing insights into a possible role
for microglia in the pathophysiology of these conditions. Unlike
mood-disorder patients who committed suicide, subjects who
had the same diagnosis but died of other causes showed no evi-
dence of brain microgliosis. However, suicidal mood-disorder
patients, including the bipolar group, had a substantial elevation in
microglia density in the dorsolateral PFC, ACC, and mediodorsal
thalamus when compared with both controls and mood-disorder
patients who did not die by suicide (154). Given the established
role of microglia in CNS inflammation, these findings raise the
intriguing possibility that suicidality might literally be a con-
sequence of the disease flare-up. Supporting a role for these
microglia changes in disease pathology is the fact that a remark-
able overlap exists between the sites of cellular pathology and the
brain regions with altered structure and function in neuroimaging
studies of bipolar illness (164).
In contrast to the evidence for a glial role in bipolar pathogene-
sis, the data supporting a role for a primary neuronal pathology in
the condition are less convincing. With a few notable exceptions,
neuronal changes in bipolar disorder are mostly morphologi-
cal in character, possibly attributable to apoptosis and thinning
of interneuronal neuropil (164), and are much less extensive
than glial pathology. Nonetheless, one study reported a 16–22%
decrease in neuronal density in the dorsolateral PFC of bipolar
disorder patients compared with a control group (165). These
large pyramidal cells are glutaminergic excitatory neurons (165).
It bears reminding that dorsolateral PFC pyramidal neurons are
the main target of thalamic projections and also provide regula-
tory feedback to the amygdala and ACC. These connections make
it likely that neuronal dorsolateral PFC pathology may result in
compromised attention, executive function, and top-down emo-
tional regulation, all of which are prominent features of bipolar
illness. Additionally, studies have detected a significant reduc-
tion in neuronal density in the hippocampus and a prominent
decrease in neuronal size in the ACC of bipolar subjects relative to
controls (166, 167).
Several studies have examined changes in monoaminergic
nuclei that may affect mood regulation. Patients with bipo-
lar disorder appear to have a higher number of noradrenergic
neurons in the locus ceruleus as well as subtle structural deficits of
serotonergic neurons in the dorsal raphe (164).
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In summary, the available evidence does not provide much
support for viewing bipolar disorder as a typical neurodegener-
ative disease. Unlike conventional neurodegenerative disorders,
which are associated with prominent neuronal loss and prominent
gliosis, glial loss seems to be the dominant cellular pathology in
bipolar illness (164). In other words, if we have to use a label, bipo-
lar disorder is much more a“gliopathic”rather than a neurodegen-
erative condition. Although the clinical correlates of the cellular
pathology in bipolar disorder await better characterization, there
is little doubt that documented pathohistological changes in key
cortico-limbic areas and the white-matter tracts play an important
role in the clinical manifestations of bipolar illness.
NEUROENDOCRINE AND AUTONOMIC DYSREGULATION IN
BIPOLAR DISORDER
Alterations in HPA axis function in bipolar disorder have been
well substantiated (168). Exaggerated release of corticotropin-
releasing factor (CRF) contributes to greater adrenocorticotropic
hormone (ACTH) secretion and a subsequent elevation of cir-
culating glucocorticoids (i.e., cortisol) (168). These disturbances
are most likely attributable to deficits in cortico-limbic regula-
tion in bipolar disorder, with consequent amygdala over-activity,
and a compromised hippocampal regulatory role (169). More-
over, glucocorticoid receptors appear to have diminished sensi-
tivity in mood disorders, possibly due to elevation in inflamma-
tory cytokines, thereby disrupting physiological feedback regu-
lation on the HPA axis and immune system (170–172). Indeed,
even euthymic bipolar patients exhibit a flattening of the corti-
sol curve (an ominous indicator of compromised overall health)
compared with healthy controls. In patients unfortunate enough
to have suffered multiple episodes, these abnormalities inten-
sify, resulting in higher overall cortisol levels in addition to
aberrant reactivity, and even greater flattening of their corti-
sol curves, compared with patients who have experienced only
a few episodes (173). Highlighting the relevance of these neu-
roendocrine abnormalities, a recent study has associated elevated
evening cortisol levels in bipolar individuals with a history of
suicidal behavior (174).
In addition to HPA dysregulation, bipolar disorder may be asso-
ciated with excessive sympathetic nervous system (SNS) activity.
For example, extra-neuronal norepinephrine was reported to be
elevated in a group of bipolar patients relative to healthy con-
trols (175). Autonomic dysregulation, more generally reflected
by decreased parasympathetic activity and elevated sympathetic
activity, may be a trait marker for bipolar disorder, as indicated
by a report of markedly lower heart rate variability in euthymic
bipolar patients than in healthy controls (176). The constellation
of SNS overactivity, parasympathetic withdrawal, glucocorticoid
receptor insufficiency, and elevated inflammatory signaling may
help account, at least in part, for the increased risk of metabolic
syndrome, endocrine disorders, and vascular disease seen in bipo-
lar patients (168, 177). Highlighting the relevance of this pattern of
neuroendocrine, autonomic and immune changes is the fact that
vascular disease has recently been identified as the leading cause
of excess death in bipolar disorder (178).
In addition to affecting autonomic and immune function, ele-
vated glucocorticoids have been associated with suppression of
thyroid-stimulating hormone secretion and compromised enzy-
matic conversion of relatively inactive thyroxine to active tri-
iodothyronine (172). An ensuing low-grade thyroid dysfunc-
tion has been associated with bipolar disorder and most likely
influences both the clinical presentation and the treatment
response (179, 180).
CIRCADIAN DYSFUNCTION IN BIPOLAR DISORDER
Multiple lines of evidence indicate a relationship between bipolar
disorders and circadian dysregulation. Circadian disturbances are
not likely to be an epiphenomenon of bipolar illness given that
they are present during mania, depression, in euthymic state, and
in healthy relatives of bipolar patients (181, 182). Actigraphic evi-
dence and polysomnography studies have detected higher density
of REM sleep, greater variability in sleep patterns, longer sleep
latency and duration, lower sleep efficiency, greater number of
arousals, fragmented sleep, and reduced daily activity, both in
actively ill and remitted bipolar patients, relative to healthy con-
trols (181–184). One study found delayed sleep phase in 62%
of bipolar depressed, 30% of MDD, and 10% of control sub-
jects (185). Other authors have pointed out that bipolar sufferers
have inherent instability and blunting of biological rhythms, ren-
dering them intolerant of shift work (186). Diminished sleep
efficiency and rhythm robustness in bipolar disorder patients have
been recently linked with abnormal dorsolateral prefrontal cortical
response and impaired performance on a working memory task
compared with healthy controls (187). Furthermore, an irregular
and delayed sleep wake cycle has been associated with the life-
time emergence of hypomanic symptoms in a non-clinical adult
sample (188).
An evening preference, in morningness–eveningness typology,
has been linked with bipolar disorder. Biological chronotype tends
to be strongly associated with biomarkers such as salivary mela-
tonin, morning cortisol, catecholamine secretion, and changes in
body temperature. Moreover, eveningness has a significant corre-
lation with important clinical manifestations of bipolar illness,
including intensity of depression, rapid mood swings, anxiety,
substance abuse, a greater sensitivity to sleep reduction, daytime
lethargy, and reduction in melatonin levels (181, 182, 186).
Altered endocrine and neurotransmitter diurnal rhythms in
bipolar disorder have also been described. In physiological cir-
cumstances circulating melatonin increases approximately 2–3 h
before sleep, remains elevated during nighttime sleep and rapidly
decreases in the morning before awakening. Circulating cortisol is
typically contra-correlated with melatonin. While high morning
cortisol levels assist with the wakening effort, low evening cortisol
supports preparation for sleep. Although there are contradictory
findings, bipolar patients may have a hypersensitive melatonin
response to light. In response to light exposure, both euthymic
and actively affected bipolar patients manifest two-fold greater
reduction of nocturnal plasma melatonin concentrations com-
pared with the healthy controls (181, 182, 186). Furthermore,
many bipolar subjects have substantially delayed and reduced
melatonin secretion compared to MDD patients (189). Distur-
bances in diurnal glucocorticoid regulation were already discussed
in the previous section, we will just add that bipolar patients have
higher awakening and evening cortisol than control groups. Even
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offspring of bipolar parents have higher afternoon salivary cortisol
compared to healthy controls (181, 182).
The secretion of several neurotransmitters is subject to circa-
dian regulation and appears to be altered in bipolar disorders.
There are rich bidirectional connections between serotonergic
nuclei raphe and the main circadian pacemaker, the hypothala-
mic suprachiasmatic nucleus (SCN). Both serotonin and mela-
tonin levels peak at night. The pace of conversion of serotonin
to melatonin is regulated by SCN. Moreover, serotonin synthesis
is subject to significant diurnal and seasonal rhythmic fluctua-
tions. Serotonin, in turn, has been found to influence transcription
of the CLOCK genes in a preclinical model (181, 182). Ventral
tegmental area dopaminergic neurons have been implicated in
regulation of REM sleep and adaptation to light, while norepi-
nephrine provides a regulatory influence on melatonin synthesis
(181, 182). The relationship between bipolar disorder and the role
of monoamines in the disturbance of circadian regulation requires
further exploration.
In contrast to large scale GWAS which have not established an
association between CLOCK genes and bipolar disorder, smaller
linkage studies, while lacking adequate replication, have noted an
association between several circadian genes, including TIMELESS,
ARNTL1, PER3, NR1D1, CLOCK, and GSK-3 beta, and the bipolar
illness (181, 182, 186).
Finally therapeutic interventions, focused on restoring proper
circadian rhythmicity, such as interpersonal and social rhythms
therapy (IPSRT) and phototherapy have received preliminary
empirical support. The use of phototherapy in bipolar disorder
is beset with controversy, as it has been reported to precipitate
serious adverse responses, such as mood instability, suicidality,
and mania (186). Controlled studies have indicated efficacy of
the IPSRT approach in extending time to recurrence of bipolar
episodes and improvement in occupational functioning. Con-
versely, alteration in treatment was associated with an increased
risk of recurrence (186). However, rigorous randomized controlled
replication of these findings will be necessary before they become
a part of routine clinical practice.
IMMUNE DISTURBANCES IN BIPOLAR DISORDER
Several limbic and paralimbic areas implicated in the pathophysi-
ology of bipolar illness, including amygdala, insula, and ACC, have
an important role in the regulation of autonomic and immune
function (102, 190–192). Although direct data are not available
linking disturbances in these limbic/paralimbic areas to inflamma-
tion in bipolar disorder, it tempting to speculate that their aberrant
activity may have a causal role in the ensuing immune dysregu-
lation that has been repeatedly observed in patients with bipolar
illness. Several studies and two recent meta-analyses have reported
elevated levels of peripheral inflammatory cytokines in bipolar
depressed and manic patients compared with healthy controls
(193–199). Both meta-analyses indicated higher levels of tumor
necrosis factor (TNF)-alpha and IL-4 in bipolar subjects relative
to healthy subjects (196, 197). Elevation of IL-4 was noted only in
the studies that did not utilize mitogen stimulation, while stim-
ulated studies demonstrated no difference in IL-4 levels between
bipolar and healthy subjects (196). IL-4 induces transformation
of naïve helper T-cells into Th2 cells and reduces production
of Th1 cells and macrophages. As such, IL-4 is a key “switch”
regulating the balance between cellular and antibody-based immu-
nity. One might speculate that IL-4 elevation in bipolar disorder
may be of compensatory nature, to buffer against the increase
of proinflammatory cytokines seen in the condition. More rigor-
ous controlled studies, accounting for medication use and mood
state effects need to be done before we can arrive at a better
understanding regarding the role of IL-4 in bipolar disorder.
Separate studies have found that both bipolar manic and
depressed patients have higher levels of TNF-alpha and IL-6 com-
pared with matched controls (193, 195, 199). Moreover, research
has established that other inflammatory markers such as high-
sensitivity C-reactive protein and chemokines tend to be elevated
in the course of bipolar episodes (200, 201). In addition to the ele-
vation of proinflammatory IL-6, common to both bipolar mood
states, bipolar depression relative to bipolar mania is characterized
by an altered balance between IL-6 and the anti-inflammatory
IL-10 (193). Based on published values, the IL-6/IL-10 ratio is
1:18 in mania and 2:44 in bipolar depression (193). Overall,
the data suggest that successful treatment leading to a euthymic
state may reverse inflammation and normalize peripheral levels of
inflammatory mediators (195, 196, 202). Inflammatory cytokines
are a known cause of diminished sensitivity of glucocorticoid
and insulin receptors (172). Combined with autonomic distur-
bance, increased platelet/endothelial aggregation and unhealthful
lifestyle, elevated inflammation may contribute to substantially
increased risk of respiratory and gastrointestinal disorders, cere-
brovascular and cardiovascular disease, and migraines in the bipo-
lar population (79, 168, 203). The cumulative impact of impaired
HPA regulation combined with compromised glucocorticoid and
insulin receptor activity, aggravated by inflammatory cytokines,
might explain the high rate of metabolic syndrome, diabetes, dys-
lipidemia, and osteoporosis in the bipolar population (88, 204).
Furthermore, increased peripheral inflammation has been asso-
ciated with numerous symptoms of mood disorders, such as
malaise, fatigue, anhedonia, impairment of concentration, anxiety,
irritability, social disconnection, hopelessness, suicidal ideation,
bodily aches, and disturbance in sleep and appetite (204–208).
Peripheral inflammatory signals can gain access to the CNS
through several pathways, as follows: (1) several brain areas are
not “covered” by the blood–brain barrier (BBB); (2) afferent vagal
fibers may convey the peripheral inflammatory signals to their
nuclei, including nucleus tractus solitarii; (3) BBB cells have the
ability to import cytokines via active transport; (4) peripheral
immune cells such as macrophages, T-lymphocytes, and mono-
cytes may gain access to the CNS and release the inflammatory
mediators; and (5) BBB cells (endothelial cells and pericytes)
can be induced to release inflammatory signals (209). Eleva-
tion of cerebrospinal fluid (CSF) inflammatory cytokines (IL-
1beta) has been substantiated in bipolar patients, especially if
they have experienced recent manic episodes, compared with
healthy volunteers (171). Imaging studies have reported periph-
eral inflammation-related changes in the activity of several limbic
and paralimbic areas, including subgenual ACC, amygdala, medial
PFC, and basal ganglia/ventral striatum/nucleus accumbens (209–
211). All of these limbic/paralimbic areas involved in the regula-
tion of mood and stress response have also been implicated in
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the pathophysiology of bipolar disorder. These referenced studies
have clear limitations, since an elevation of peripheral inflamma-
tory cytokines was elicited by the injections of typhoid vaccine
or endotoxin (210, 211), and therefore cannot be readily trans-
posed to the processes that take place in the context of mood
disorders. Nonetheless, it is intriguing that elevation of inflam-
matory cytokines in the CNS has been associated with suppressed
synthesis of neurotrophic factors (especially BDNF) and compro-
mised monoaminergic transmission (204), both of which have
been reported in bipolar disorder.
Inflammatory cytokines activate microglia in the brain, caus-
ing their phenotypical transformation. Active microglia amplify
inflammatory signals by releasing reactive oxygen species, reac-
tive nitrogen species, cytokines, and chemokines (see Figure 3).
This chemical cocktail of oxidative stress and inflammatory sig-
nals precipitates a change in astroglial function. Glial indoleamine
2,3-dioxygenase (a tryptophan metabolizing enzyme) is up-
regulated, resulting in greater production of neurotoxic kynure-
nine metabolites and quinolinic acid (QA) (102, 209, 212, 213).
Altered astroglia diminish their neurotrophic production (includ-
ing BDNF and GDNF – glial cell line-derived neurotrophic factor)
and start extruding inflammatory cytokines and glutamate. Glu-
tamate released from astroglia accesses extra-synaptic N -methyl-
d-aspartate (NMDA) receptors, causing suppression of BDNF
synthesis and activation of the proapoptotic cascade. QA is a
potent NMDA agonist that may further potentiate excitotoxic-
ity (209, 212). Furthermore, proinflammatory cytokines increase
the expression of 5HT and dopamine transporters, further dis-
rupting monoamine signaling (207, 209). Increased oxidative
stress may further compromise monoamine synthesis by deplet-
ing BH4 (tetrahydrobiopterin), a key coenzyme in monoamine
synthesis (207, 213). Elevated CSF IL-6 in a group of suicidal
mood-disordered patients that included several bipolar subjects
correlated with more rapid 5HT and dopamine turnover, as evi-
denced by increased levels of their metabolites (214). Less efficient
monoamine signaling was correlated with higher levels of IL-6 and
reflected in greater severity of depressive symptoms (214). Finally,
a recent imaging study reported a correlation between increased
expression of inflammatory genes and a greater hemodynamic
response to emotional stimuli in vmPFC, amygdala, and hip-
pocampus of mood-disordered patients (the group included eight
bipolar subjects) relative to healthy controls. In the same study,
elevated expression of inflammatory genes was also linked with
decreased thickness of the subgenual ACC, hippocampus, and cau-
date in the mood-disordered group (213). In summary, immune
dysregulation in bipolar disorder is associated with alterations
in monoamine and glutamate signaling, impaired neuroplastic-
ity and neurotrophic support, and changes in glial and neuronal
function, most likely contributing to the symptomatic expression
and medical comorbidities of this mood disorder.
CHANGES IN NEUROPLASTICITY AND NEUROTROPHIN
SIGNALING
The role of BDNF in mood disorders has received more attention
than other members of the neurotrophin family. It is involved in
neuronal maturation, differentiation and survival, synaptic plas-
ticity, and long-term memory consolidation (215). Furthermore,
compelling preclinical evidence suggests that BDNF plays an
important role in regulating the release of serotonin, glutamate,
and gamma-aminobutyric acid (GABA), as well as in slow-wave
sleep modulation (216, 217). BDNF expression is particularly high
in the cerebral cortex and hippocampus (215).
Evidence suggests that stress and excessive, inadequately reg-
ulated glucocorticoid signaling may interfere with hippocampal
neurogenesis in the context of bipolar illness (218). The hippocam-
pus plays an important role in the inhibitory regulation of the
HPA axis; therefore, impairment in its plasticity may have a rele-
vant role in the pathophysiology of bipolar disorder. Individuals
endowed with at-risk alleles of the BDNF gene may have com-
promised ability to normalize HPA axis activity, thereby adding to
mood-disorder pathology (219). In addition to its role in regulat-
ing the neuroplastic processes, BDNF also acts as a resilience factor,
assisting the maturation and differentiation of the nerve cell prog-
enitors (220). Furthermore, BDNF even acts as an immunomod-
ulator in the periphery of the body (221). There seems to be a
bidirectional communication between the immune system and
neuroplasticity regulators. In fact, recent preclinical research has
identified microglia-originated BDNF as a key contributor to neu-
ronal tropomyosin-receptor-kinase-B (TrkB) (a BDNF receptor)
phosphorylation and ensuing changes in synaptic plasticity. Thus,
microglia BDNF release appears to have a central role in learning
and memory-related synaptic plasticity (222). BDNF is released
from neurons in two forms: as pro-BDNF (pBDNF), and its chem-
ically abbreviated version, mature BDNF (mBDNF). These two
molecules (pBDNF and mBDNF) participate in opposing func-
tions: pBDNF binds to p75 receptor, initiating apoptosis, or shriv-
eling of neurons, whereas, mBDNF has primary affinity for the
TrkB receptor, which mediates neuroplasticity and resilience (223,
224). There are three different alleles of the gene regulating BDNF
synthesis, depending on the valine to methionine substitution at
position 66 of the pro-domain: val66met, val66val, and met66met.
Met variants are accompanied by decreased BDNF distribution
in the dendrites and impairment in regulated secretion, and are
considered to be “vulnerability” alleles in mood disorders (223).
Genetic studies have implicated this BDNF gene polymorphism in
the risk for bipolar disorder, early disease onset, rapid cycling, sui-
cidality associated with mood episodes, and treatment response
(225–228). Several clinical studies have demonstrated decreased
levels of BDNF in bipolar depressed and manic patients (215). Low
levels of BDNF were correlated with clinical severity of depression
and mania (229, 230). Although diminished BDNF levels were
reported in both treated and untreated bipolar subjects, one study
found normal levels of BDNF in euthymic, treated patients, sug-
gesting a potential neurotrophic benefit of pharmacotherapy (215,
229). A reciprocal relationship between BDNF and inflammatory
mediators is an important marker of the progression of bipolar
disease. Chronicity of bipolar illness, repeated episodes, and aging,
all have a synergistic impact on a decline of neurotrophic signaling
and increase in inflammation (215, 231–234). In the later stages of
bipolar disorder, an imbalance between inflammatory cytokines
(especially TNF-alpha), mediators of oxidative stress, and BDNF
persists even between episodes and is associated with metabolic
disruption, progression of structural brain changes, and neurocog-
nitive decline (85, 215, 231, 235). In fact, some authors associate
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FIGURE 3 | (A) Glial–neuron interactions: normal conditions. Glial–neuron
interactions under non-inflammatory conditions. This image illustrates the
relationship between glial cells and a “typical” glutamate neuron. Numbers in
legend refer to corresponding numbers on image. Glial cell functioning is
critical to sustaining and optimizing neuronal functioning in the CNS. The three
types of glial cells are microglia, oligodendrocytes, and astroglia. Microglia act
as ambassadors of the immune system (1), monitoring for derivatives of
peripheral inflammatory signals. Oligodendrocytes optimize neuronal
signaling by myelination of neurons (2). Astrocytes serve a number of
functions including: maintenance of the blood–brain barrier and facilitation of
neurovascular coupling (3); protection of the neuronal synapse (4) by
removing excess ions to keep firing rate steady and removing excess
glutamate before it can diffuse out of the synapse to bind to extrasynaptic
NMDA receptors (which are implicated in neurotoxicity); (5) release of ATP to
reduce neuronal glutamate release; (6) calming and stabilizing microglia via
release of ATP, GABA, and TGFβ; providing trophic support via BDNF and
GDNF to neurons, microglia, and oligodendrocytes (7).
(Continued)
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FIGURE 3 | Continued
GDNF released by the astrocyte also supports the functioning of astrocytes
themselves via an autocrine signaling pathway (8). Abbreviations: NMDA,
N -methyl-d-aspartate; GABA, gamma aminobutyric acid; TGFβ, transforming
growth factor beta; BDNF, brain-derived neurotrophic factor; GDNF, glial
cell-derived neurotrophic factor; ATP, adenosine triphosphate. (B) Response to
dysregulated peripheral inflammatory signals. Response to peripheral
inflammatory signals. Microglia detect derivatives of the peripheral
inflammatory signals such as ones conveyed by perivascular macrophages,
and propagate/transduce this signal to the central nervous system through
release of ATP, cytokines, chemokines, RNS, and ROS (1). The inflammatory
mediators released by microglia initiate a positive-feedback loop in which
astrocytes also begin to release ATP and cytokines, which triggers further
inflammatory cytokine release from microglia, thus perpetuating the
inflammatory cycle (2). Increased levels of ATP and inflammatory mediators
lead to a cascade of events that result in destabilization and impairment of the
normal functioning of both glial and neurons. Astrocytes become unable to
maintain the integrity of the blood–brain barrier and optimal neurovascular
coupling (3). Instead of removing excess glutamate from excitatory synapses,
activated astrocytes release additional quantities of this neurotransmitter,
producing an excess of glutamate that may impair synaptic communication
(4) and lead to excitotoxicity via stimulation of extrasynaptic NMDA receptors.
Activated astrocytes decrease release (indicated by dashed lines) of GABA (5)
which results in destabilization of microglia such that they become amoeboid
in shape and able to move throughout the brain while continuing to release
inflammatory cytokines and ATP. Activated astroglia also reduce the release of
neurotropic factors, such as BDNF and GDNF (6). The decline in BDNF and
GDNF further perpetuates microglia activation, precipitating impairment in
oligodendrocyte function and demyelination, as well as neuronal apoptosis.
Activated microglia exhibit increased activity of the enzyme indoleamine
2,3-dioxygenase, which eventually converts tryptophan into quinolinic acid
(QA). Increased metabolism of tryptophan to quinolinic acid may interfere
with serotonin signaling due to depletion of tryptophan, while released
quinolinic acid contributes to neurotoxicity via stimulation of extrasynaptic
NMDA receptors (7). Abbreviations: RNS, reactive nitrogen species; ROS,
reactive oxygen species; ATP, adenosine triphosphate; BDNF, brain-derived
neurotrophic factor; GDNF, glial cell-derived neurotrophic factor; GABA,
gamma aminobutyric acid; TGFα, transforming growth factor alpha.
progression in bipolar disorder-related cognitive decline with a
greater reduction in BDNF signaling (79). However, there are sev-
eral areas regarding the role of BDNF in bipolar disorder that need
further clarification. We are not to misconstrue elevated BDNF
signaling as a universally positive sign. BDNF increases in the
nucleus accumbens and amygdala may be associated with addictive
behaviors and negative affect, respectively (236). Therefore, better
determination of the aberrant regional BDNF distribution in the
brains of bipolar patients, as well as understanding the dynamic of
BDNF fluctuations as they relate to bipolar symptoms and treat-
ment response may provide us with clinically useful information.
Moreover, we need to further elucidate the relationship between
peripheral and central BDNF levels, as well as altered dynamics
between proBDNF and mBDNF in the context of bipolar illness.
Moreover, serum neurotrophin-3, neurotrophin-4/5, and
GDNF are also altered in bipolar disorder (215). GDNF is an
important regulator of neuroplasticity, monoamine and GABA
signaling, and microglia activation (237–240). Findings of studies
investigating peripheral GDNF levels in bipolar disorder are less
consistent than those in BDNF research. Euthymic bipolar patients
were reported to have either similar or elevated GDNF levels com-
pared with healthy controls (237, 241). Although some studies
detected reduced GDNF levels in manic patients that correlated
with symptom severity, others found elevated GDNF in mania
(237, 241). Unlike depressive episodes in MDD, which tend to be
associated with a reduction of GDNF, bipolar depression does not
seem to influence GDNF levels (237). A recent randomized con-
trolled trial evaluated the impact of treatment on serum GDNF
levels in bipolar patients. At baseline serum GDNF concentra-
tions were reduced in both medication-free manic and depressed
bipolar patients, compared to the control group. After 8-weeks of
therapy with mood-stabilizers and antipsychotics, remitted bipo-
lar patients had similar GDNF serum levels as healthy controls,
indicating a “normalizing” effect of the successful pharmacolog-
ical treatment (240). Differences in methodology, patients’ age,
and medication status may explain some of the discrepancies
in outcomes of GDNF studies in bipolar disorder. Additionally,
variability in GDNF findings may be a reflection of a biological
heterogeneity within bipolar disorder. Given the importance of
glial pathology in the pathogenesis of bipolar disorder and the key
role played by GDNF in stabilizing microglia activation and the
propagation of peripheral inflammatory signaling in the CNS, we
hope that future, methodologically rigorous studies may elucidate
its disease state-dependent changes.
ALTERATIONS IN GABA, GLUTAMATE, AND MONOAMINE
TRANSMISSION
Early research into the role of monoamine disturbances in bipo-
lar disorder followed the path set by MDD studies. A study
that included a mix of MDD and bipolar depressed patients
noted an association between elevated CSF levels of 3-methoxy-4-
hydroxyphenylglycol (MHPG), a norepinephrine metabolite, and
agitation and anxiety in depressed patients (242). Additionally,
studies reported diminished immunoreactivity of locus coeruleus
processes and decreased CSF MHPG in suicidal bipolar subjects
compared with controls (243, 244).
A recent review utilized cumulative pharmacological and imag-
ing evidence to put forth the hypothesis of dopaminergic dysfunc-
tion in bipolar illness. This idea posits that excessive dopaminergic
activity in the course of mania precipitates dopamine receptor
down-regulation, which subsequently triggers a transition into a
depressed state (245). Moreover, studies linking the severity of
bipolar symptoms to tardive dyskinesia, even in the absence of
pharmacotherapy, lend further support to claims of dopamine
dysfunction in this disease state (246). Unfortunately, definitive
and more direct evidence implicating dopamine in the etiology of
bipolar disorder is still unavailable.
Brain imaging data implicating serotonin transporter (5HTT)
binding in the pathophysiology of bipolar disorder are mixed, at
best. An initial study of depressed, unmedicated bipolar patients
reported increased 5HTT binding in the thalamus, dorsal ACC,
medial PFC, and insula, and decreased binding in serotoninergic
brainstem nuclei raphe compared with controls (247). A subse-
quent study noted reduced 5HTT binding in midbrain, amygdala,
hippocampus, thalamus,putamen,and ACC of unmedicated bipo-
lar depressed subjects compared with matched controls (248).
Finally, a case report of a patient experiencing mixed mania,
utilizing single-photon emission computed tomography imaging,
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detected elevated 5HTT binding in the midbrain and dopamine
transporter binding in the striatum, which normalized after a year
of psychotherapy (249). In conclusion, evidence of monoamine
involvement in the etiology of bipolar disorder is for the most
part indirect, inconsistent, and lacking replication in larger scale
studies.
Relatively few studies have focused on abnormalities of GABA
transmission in bipolar disorder. Recent studies have reported sig-
nificantly increased GABA platelet uptake in bipolar depressed
patients and decreased GABA uptake during mania (250). By con-
trast, glutamate platelet uptake was increased in the course of
manic episodes relative to healthy controls. Altered platelet GABA
and glutamate uptake correlated with the severity of depression
and mania, respectively, as measured by standardized scales (250).
Another study in euthymic bipolar patients, using magnetic reso-
nance spectroscopy noted an increase in the GABA/creatinine ratio
compared with healthy controls (251). Researchers have attempted
to differentiate GABA transmission in unipolar depressed from
bipolar depressed patients by analyzing glutamic acid decarboxy-
lase (GAD) immunoreactive (ir) neuropil. GAD is the key enzyme
in GABA synthesis. Unipolar depressed patients had a greater den-
sity of GADir neuropil in lateral dorsal thalamic nuclei, whereas
bipolar depressed patients manifested a GADir decrease in dor-
solateral PFC, compared with patients with MDD and healthy
controls (252). This study suggests significant regional differences
in GABA transmission between unipolar and bipolar depression.
Research into the expression of genes related to ionotropic
glutamate receptors in bipolar disorder is relatively consistent,
especially in relation to hippocampal glutamatergic abnormali-
ties (253, 254). Studies noted a significant decrease in expression
of the NR1 and NR2A subunits of NMDA glutamate receptors in
the hippocampus and a significant increase in the expression of
vesicular glutamate transporter-1 (VGluT1) in the ACC of bipolar
subjects relative to a control group (255, 256).
An ongoing molecular dialog between glial cells and neurons
has an important role in the regulation of glutamate signaling.
Glutamate released from neurons is taken up by glial cells and con-
verted to glutamine before being returned to neurons as the “raw
material” for further neurotransmitter synthesis (257). In certain
circumstances, astroglial cells are also capable of glutamate release
(258, 259). Neuronal NMDA receptors respond to these astro-
cytic signals by elevating excitatory glutamatergic transmission
(260). Reduction in both neuronal NMDA activity and astro-
cytic kainate receptor-mediated glutamate signaling by mood-
stabilizing agents has been noted to have antidepressant activity in
bipolar disorder (261). An MRS study has indicated an elevation in
glutamine/glutamate ratio in the ACC and parieto-occipital cor-
tex of manic subjects compared with matched controls, pointing
to excessive glutamatergic activity and/or aberrant glial/neuronal
interactions in the context of bipolar illness (257).
Several MRS studies and a postmortem study have reported an
increase in glutamatergic transmission in the frontal cortex and
hippocampus of bipolar subjects relative to control groups (262–
264). Interpretation of MRS findings requires caution, however,
because brain glutamate has functions other than neurotransmis-
sion. Proton magnetic resonance spectroscopy (1H MRS) pro-
vides an opportunity for in vivo evaluation of glutamate-related
metabolites, depending on field strength and signal-to-noise ratio,
glutamate and glutamine can be quantified either separately or as a
composite of glutamate, glutamine, GABA, and other metabolites
(most often labeled as Glx) (265). Aside from being the most plen-
tiful neurotransmitter in the brain, glutamate is also a substrate
in protein metabolism, and a precursor for glutamine, GABA, and
glutathione. Unfortunately, MRS signals are of little aid of differen-
tiating synaptic glutamate from the intracellular glutamate-related
compounds (266). Multiple storage locations, difficulty discerning
glutamate-related metabolites from each other and their diverse
roles makes precise interpretation of MRS Glx signal a daunting
challenge. However, since GABA represents only a minor fraction,
one can reasonably approximate Glx as a representative of com-
bined glutamine and glutamate, 80% of which is stored in synaptic
vesicles, while 20% is in adjacent astrocytes awaiting conversion to
glutamine (266).
Recent comprehensive meta-analyses have identified relatively
consistent (albeit with a few discrepant findings) elevation of
Glx in ACC, medial PFC, DLPFC, parieto-occipital cortex, insula,
and hippocampus. These findings persisted across the bipolar
mood states and even in euthymic bipolar patients, relative to
the control group (265). Effect sizes related to Glx signal were
more robust in mania and depression than in euthymic patients
(266). One can speculate that at least some of the glutamatergic
abnormality in bipolar disorder reflects functional and numeri-
cal glial abnormalities given their cardinal role in regulation of
glutamate metabolism and signaling (266). Distribution of aber-
rant Glx signals in bipolar disorder also substantially overlaps
with glial alterations reported in the post-mortem cytological
studies. Anatomical structures characterized by anomalous MRS
signals in bipolar disorder are some of the key components of
the cortico-limbic regulatory pathways, involved in regulation of
mood, cognitive processing, autonomic, and endocrine response.
It would be plausible to assume that altered glutaminergic signal-
ing in these principal cortico-limbic circuits may be reflected in
diverse bipolar clinical symptomatology.
Glutamatergic findings in bipolar disorder were similar
whether the patients were medicated or not. Interestingly, one of
the studies demonstrated an inverse relationship between diurnal
salivary cortisol levels and hippocampal glutamate concentration
in bipolar patients (262). This finding reaffirms a critical link
between neuroendocrine disturbance and glutamate transmission
in bipolar disorder, implicating this key area involved in memory,
emotional regulation, and stress response.
Overall, multiple, consistent, and convergent evidence from
genetic, postmortem, biochemical, and imaging studies points to a
principal role of glutamatergic dysregulation in the etiopathogen-
esis of bipolar disorder. Moreover, evidence links aberrant glial–
neuron interactions and endocrine dysregulation with alterations
in glutamatergic transmission.
CHANGES IN THE INTRACELLULAR SIGNALING CASCADES
It is becoming increasingly evident that current mood-stabilizing
agents have actions that extend beyond binding to neuronal
membrane surface receptors. Therapeutic actions of psychotropics
utilized in the treatment of bipolar disorder most likely rely on
an interface with intracellular signaling cascades and eventual
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enduring changes in gene expression, accompanied by alter-
ations in neurotransmission and neuroplasticity. Better under-
standing of intracellular signaling cascades may therefore provide
valuable insights into the underlying causes of bipolar disorder
and subsequently to more effective treatment strategies.
The phosphoinositide-3-kinase (PI3K)/AKT pathway is a gen-
eral signal transduction pathway for growth factors, including
BDNF and consequently for BCL-2. The GSK-3 signaling path-
way modulates apoptosis and synaptic plasticity. Increased activity
in the GSK-3 pathway supports apoptosis. Attenuation of GSK-
3 activity leads to up-regulation of BCL-2 and beta-catenin and
consequent enhancement of neuroplasticity and cellular resilience.
This pathway is also involved in circadian regulation (60, 61).
Interestingly, manipulation of the GSK-3 pathway produces
both antimanic and antidepressant effects. Many agents with
mood-stabilizing properties, such as lithium, valproate, and atyp-
ical antipsychotics, directly and indirectly modulate the PI3K,
GSK-3, and Wnt signaling pathways, the very same ones implicated
in genetic studies of bipolar disorder (267, 268).
There is another surprising outcome from genetic studies of
bipolar disorder: the affected stress-activated kinase pathways do
not target neurotransmitter trafficking; they are funneled toward
regulating oligodendroglia (61). Thus, the convergence of genetic
vulnerabilities in bipolar disorder appears to particularly target
oligodendrocyte function (61), inviting speculation about the role
of stress and circadian dysregulation in precipitating white matter
changes in cortico-limbic pathways, which are critical for proper
mood regulation.
CHANGES IN SYNAPTIC FUNCTION, BIOENERGETICS, AND
OXIDATIVE METABOLISM
Convergent evidence from imaging, neurochemical, and genetic
studies points to disturbances in bioenergetics and mitochon-
drial function in the context of bipolar illness (268, 269). A
substantial portion of genes implicated in the etiology of bipolar
disorder code for mitochondrial proteins. Hippocampal expres-
sion of genes related to mitochondrial proteins was substantially
reduced in bipolar compared with control subjects (270). Pre-
viously described disease-related functional alterations in brain
circuitry may have a reciprocal relationship with mitochondrial
function. Namely, genetic control of mitochondrial function is
influenced by the level of neuronal activity (268).
Beyond its well-known role in cellular bioenergetics, proper
mitochondrial function is important for the regulation of neu-
roplasticity, apoptosis, and intracellular calcium levels. Of course,
dynamic changes in endocellular calcium have a crucial role in
the modulation of intracellular signaling cascades and neuro-
transmitter release (271). Furthermore, compromised mitochon-
drial function may be reflected in aberrant oxidative metabolism,
down-regulated adenosine triphosphate-dependent proteasome
degradation, and ensuing DNA damage contributing to neuronal
apoptosis (270, 272).
The accelerated telomere shortening found in bipolar disor-
der may also be a consequence of stress-related oxidative dam-
age. A recent study suggested that telomere shortening in mood
disorders, most likely attributable to oxidative stress, may be
equivalent to 10 years of accelerated aging (273).
INTEGRATION OF NEUROBIOLOGICAL FINDINGS
As we noted at the beginning of this review, from a neurobiologi-
cal perspective, there is no such thing as bipolar disorder. Rather,
it is almost certainly the case that there are many somewhat sim-
ilar, but subtly different, pathological conditions that produce a
final common pathway disease state that we currently diagnose
as bipolarity. This heterogeneity – reflected in the lack of synergy
between our current diagnostic schema and our rapidly advancing
scientific understanding of the condition – puts a hard limit on all
attempts to articulate an integrated perspective on bipolar disor-
der. Also posing a challenge to the integrative enterprise is the fact
that nothing could be further from a static condition than bipolar
disorder. Whereas, most psychiatric conditions vacillate within a
single register between symptom exacerbation and various degrees
of recovery, those attempting to fully understand bipolar disorder
must contend with the fact that exacerbations come in two distinct
flavors – manias and depressions – and that often these exacerba-
tions can take any of a nearly infinite number of combinations of
these two mood disturbances.
Despite these challenges, scientific findings in recent years are
beginning for the first time to offer a provisional “unified field
theory” of the disease. The very fact that no single gene, pathway,
or brain abnormality is likely to ever account for the condition
is itself an extremely important first step in better articulating an
integrated perspective on both its ontological status and patho-
genesis. Whether, this perspective will translate into the discovery
of innumerable more homogeneous forms of bipolarity is one of
the great questions facing the field and one that is likely to have
profound treatment implications, given the fact that such a dis-
covery would greatly increase our ability to individualize – and by
extension, enhance – treatment.
It is intriguing that despite the primacy given to functional neu-
roimaging methodologies in current psychiatric research, results
from fMRI are among the least consistent in the context of bipo-
lar disorder in terms of separating bipolar patients from healthy
controls and from other psychiatric conditions, as well as for dif-
ferentiating mania from depression. More consistent findings have
emerged at a cellular level, providing evidence that bipolar disorder
is reliably associated with dysregulation of glial–neuronal inter-
actions and with abnormalities more apparent in glial elements
than in neurons. Among these glial elements are microglia – the
brain’s primary immune elements, which appear to be overactive
in the context of bipolarity. Multiple studies now indicate that
inflammation is also increased in the periphery of the body in
both the depressive and manic phases of the illness, with at least
some return to normality in the euthymic state. These findings are
consistent with changes in the HPA axis, such as reduced sensi-
tivity to glucocorticoids, which are known to drive inflammatory
activation.
Further evidence that classification schemes based on the sci-
ence of the future will share only minimal overlap with our
current diagnostic categories comes from recent data in genet-
ics, neuroscience, and immunology demonstrating that bipolar
disorder shares many features with other conditions, especially
schizophrenia and unipolar depression, which we currently con-
ceptualize as separate disease states. Recent genetic studies identify
many risk loci shared by these conditions. Although some of these
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risk alleles primarily target CNS functioning, many others have
far more basic “housekeeping” functions within most cells in the
body. These findings provide a novel insight into other recent dis-
coveries linking bipolar disorder to abnormalities in metabolism
and general and mitochondrial function in particular. Moreover,
the fact that bipolarity reaches so deeply into the core processes of
life itself may enrich our understanding of why the disorder is so
reliably associated with immune abnormalities and with a marked
escalation in risk for the development of multiple medical condi-
tions that account for much of the increased mortality associated
with the disorder.
Given the dynamic nature of interactions among microglia,
astroglia, and oligodendroglia – all of which influence synaptic
activities essential to mental functioning – it should perhaps not be
surprising that bipolar disorder in particular, and psychiatric con-
ditions in general, remain hard to characterize using monolithic
diagnostic, or even physiological, criteria. Adding to the complex-
ity inherent in glial–neuronal interactions is the fact that these
interactions are further influenced by neural transmission, as well
as immune, endocrine, and neurotrophic signaling. The sum of
these signals affects intracellular signaling cascades which, in turn,
initiate changes in gene expression that initially cause functional
changes that over time alter the very structure of the brain itself.
As a result of disrupted homeostatic functioning at multiple levels
ranging from the molecular to the environmental, one maladaptive
change begets another in bipolar disorder. Macroscopic alterations
drive microscopic ones, and vice versa.
In this review, we have emphasized the complexity of bipolar
illness, not just because this is what current science suggests, but
also because this perspective implies a need for parallel dynamic
changes in the ways we diagnose and treat the condition. For exam-
ple, bipolar disorder will not look the same in teenage years, adult-
hood, and senescence. As our scientific understanding advances,
we suspect that we will gain greater understanding of how the
ever-changing nature of the disease process requires different
combinations of therapeutic interventions, with these treatment
modalities tracking changes in the substrate and pathophysio-
logical mechanisms of the disease in an iterative manner. Said
differently, to significantly advance how we treat bipolar disorder,
we will need to replace unidimensional (i.e., purely phenomeno-
logical diagnoses) and static (i.e., based on the assumption that
the appearance and underlying pathophysiology of the disease do
not evolve over time) diagnostic and treatment approaches with
strategies that are dynamic and integrated (i.e., including elements
such as psychotherapy, pharmacotherapy, exercise, nutrition, med-
itation, relationship healing, etc.) as well as multi-level (i.e., based
on phenomenology, neuroimaging, and biochemical and genetic
evaluation).
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